Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
Study sponsor: Biofrontera Inc. · BFRI
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-03-19Actual
Enrollment · participants187Actual
Source updated2026-01-14Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.